Success Story: NIW Approved for a Bioinformatics Specialist Building Computational Pipelines That Accelerate Biomedical Discovery
Client’s Testimonial:
"I had a great experience working with Chen Immigration Attorneys on my EB2-NIW petition. They demonstrated strong expertise, clear communication, and attention to detail throughout the process.
Their guidance in presenting my work and aligning it with the national interest criteria was invaluable. The team was responsive, organized, and made the process smooth from start to approval.
I highly recommend their services for EB2-NIW petitions.”
On March 7th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Staff Associate in the Field of Bioinformatics (Approval Notice).
General Field: Bioinformatics
Position at the Time of Case Filing: Staff Associate
Country of Origin: India
State of Residence at the Time of Filing: Massachusetts
Approval Notice Date: March 7th, 2026
Processing Time: 16 months, 7 days (Premium Processing Upgrade Requested)
Case Summary:
In modern biomedicine, many of the biggest breakthroughs start with the same bottleneck, turning massive, high-throughput biological datasets into results that researchers can actually use. In this case, the I-140 National Interest Waiver petition showed that the client’s work in bioinformatics addresses that bottleneck directly by developing computational tools and pipelines that expand what scientists can learn from complex biological data and move the field closer to new disease treatments.
What the client does and why it matters
The client holds an M.Sc. in bioinformatics and is currently employed as a staff associate. The proposed endeavor is to continue developing novel computational tools and pipelines that improve biological understanding and enable the discovery of treatments for diseases.
To keep the endeavor concrete and adjudicator-friendly, the petition highlighted real research directions already underway, including analyzing high-throughput multidimensional omics data to study neurodegeneration and other central nervous system diseases, and developing computational approaches that support stem cell and epigenetic research.
How we demonstrated the client’s influence without overstating metrics
The petition presented objective evidence of peer-validated output and independent reliance, including:
- 8 peer-reviewed journal articles, including 4 first-authored, plus 2 preprints
- 278 citations to the client’s published work
Rather than treating citations as a popularity score, we framed them the way USCIS evaluates NIW evidence. Citations are persuasive when they show independent researchers are using the client’s methods and findings as inputs to their own studies. The petition further strengthened this point by showing that multiple papers ranked among the most highly cited in the field for their publication years, including two papers in the top 1% and two papers in the top 10% in Biology and Biochemistry for their respective years. This type of time-normalized evidence helps an adjudicator see that the influence is strong relative to other work published in the same period, not simply accumulated over time.
Funding as an objective national interest anchor
The petition also documented major funding support from the National Institutes of Health and the National Heart, Lung, and Blood Institute. We used this as an additional credibility anchor because competitive federal funding is typically reserved for research aligned with clear U.S. public health priorities.
Recommendation letters
We included 4 recommendation letters from field experts, including an independent advisory opinion, to validate the originality of the client’s work and confirm its broader importance to biomedical research and therapeutic discovery.
“Certainly, he has solidified his position as a valuable authority in this area of the field.”
The result
The I-140 NIW petition was approved, reflecting a clear presentation of national importance, a well-supported showing that the client is positioned to advance the endeavor, and a practical explanation of why granting the waiver benefits the United States by enabling continued progress on computational tools that strengthen biomedical discovery and treatment development.